Genmab A/SGMABNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
257.13%
Near historical average
Percentile
P77
Within normal range
Streak
2 qtr
Consecutive growthStable
Average
237.90%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 257.13% |
| Q3 2025 | 36.42% |
| Q2 2025 | -79.85% |
| Q1 2025 | 497.35% |
| Q4 2024 | -83.94% |
| Q3 2024 | 828.31% |
| Q2 2024 | 0.00% |
| Q1 2024 | -86.90% |
| Q4 2023 | -17.92% |
| Q3 2023 | 367.20% |
| Q2 2023 | -86.52% |
| Q1 2023 | 712.81% |
| Q4 2022 | -79.78% |
| Q3 2022 | 105.21% |
| Q2 2022 | 63.37% |
| Q1 2022 | 143.57% |
| Q4 2021 | -46.09% |
| Q3 2021 | 25.92% |
| Q2 2021 | -70.04% |
| Q1 2021 | 248.50% |
| Q4 2020 | -115.71% |
| Q3 2020 | 2024.69% |
| Q2 2020 | -87.51% |
| Q1 2020 | 993.71% |
| Q4 2019 | -45.16% |
| Q3 2019 | 72.67% |
| Q2 2019 | -71.45% |
| Q1 2019 | 217.10% |
| Q4 2018 | -3.61% |
| Q3 2018 | 56.99% |
| Q2 2018 | -70.94% |
| Q1 2018 | 84.85% |
| Q4 2017 | 498.20% |
| Q3 2017 | -92.29% |
| Q2 2017 | -27.65% |
| Q1 2017 | 1060.61% |
| Q4 2016 | -138.24% |
| Q3 2016 | -2.49% |
| Q2 2016 | 2530.82% |
| Q1 2016 | -103.43% |